Moderate-to-severe
Adolescent
Adult
Aged
Aged, 80 and over
Animals
Antivenins
/ adverse effects
Child
Child, Preschool
Databases, Factual
Female
Humans
Immunoglobulin Fab Fragments
/ adverse effects
Length of Stay
Male
Medical Audit
Middle Aged
Patient Admission
Poison Control Centers
Prospective Studies
Severity of Illness Index
Snake Bites
/ diagnosis
Time Factors
Treatment Outcome
United Kingdom
Viper Venoms
/ antagonists & inhibitors
Viperidae
/ metabolism
Young Adult
Vipera
ViperaTAb
antivenins
snakebite
snakes
Journal
Clinical toxicology (Philadelphia, Pa.)
ISSN: 1556-9519
Titre abrégé: Clin Toxicol (Phila)
Pays: England
ID NLM: 101241654
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
pubmed:
16
3
2021
medline:
9
11
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
Bites by the European adder ( A prospective audit of ViperaTAb use was conducted from March 2016 until November 2020 by the UK National Poison Information Service (NPIS). Users of the NPIS online toxicology database, TOXBASE, considering the use of antivenom for One hundred and seventy patients were administered ViperaTAb antivenom over five years. One hundred and thirty-two were adults and 38 children (median age and range: 38, 2-87 years). Bites occurred across the UK, but most commonly in coastal regions of Wales and of South-West and East England. Median time to presentation was 2.1 (IQR 1.5-4.0) h and to antivenom administration from presentation was 2.0 (IQR 0.9-3.6) h. A minority of patients presented to hospital more than 12 h after being bitten ( ViperaTAb antivenom appears to be effective and safe and should be administered as soon as possible for patients meeting clinical criteria. Patients require close observation following antivenom to detect adverse reactions and progression or recurrence of envenoming. Close collaboration with expert NPIS consultant advice can help optimise antivenom timing, ensure repeated dosing is given appropriately, and avoid unnecessary surgical intervention. All hospitals, particularly those located in areas of relatively high incidence, should stock sufficient antivenom available at short notice, 24 h a day.
Sections du résumé
BACKGROUND
BACKGROUND
Bites by the European adder (
METHODS
METHODS
A prospective audit of ViperaTAb use was conducted from March 2016 until November 2020 by the UK National Poison Information Service (NPIS). Users of the NPIS online toxicology database, TOXBASE, considering the use of antivenom for
RESULTS
RESULTS
One hundred and seventy patients were administered ViperaTAb antivenom over five years. One hundred and thirty-two were adults and 38 children (median age and range: 38, 2-87 years). Bites occurred across the UK, but most commonly in coastal regions of Wales and of South-West and East England. Median time to presentation was 2.1 (IQR 1.5-4.0) h and to antivenom administration from presentation was 2.0 (IQR 0.9-3.6) h. A minority of patients presented to hospital more than 12 h after being bitten (
CONCLUSION
CONCLUSIONS
ViperaTAb antivenom appears to be effective and safe and should be administered as soon as possible for patients meeting clinical criteria. Patients require close observation following antivenom to detect adverse reactions and progression or recurrence of envenoming. Close collaboration with expert NPIS consultant advice can help optimise antivenom timing, ensure repeated dosing is given appropriately, and avoid unnecessary surgical intervention. All hospitals, particularly those located in areas of relatively high incidence, should stock sufficient antivenom available at short notice, 24 h a day.
Identifiants
pubmed: 33720783
doi: 10.1080/15563650.2021.1891245
doi:
Substances chimiques
Antivenins
0
Immunoglobulin Fab Fragments
0
Viper Venoms
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM